# A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01028963` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01028963](<https://clinicaltrials.gov/study/NCT01028963>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01028963

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

## Technical summary

Registry record NCT01028963. Randomized; triple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 159 participants (enrolled count; ClinicalTrials.gov record NCT01028963, source copy `cardio:ctgov-nct01028963-2025-03-06`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01028963, source copy `cardio:ctgov-nct01028963-2025-03-06`, retrieved 2026-10-26)
- Primary completion: 2010-10 (actual) (ClinicalTrials.gov record NCT01028963, source copy `cardio:ctgov-nct01028963-2025-03-06`, retrieved 2026-10-26)
- Completion: 2010-11 (actual) (ClinicalTrials.gov record NCT01028963, source copy `cardio:ctgov-nct01028963-2025-03-06`, retrieved 2026-10-26)
- Countries: Australia; Czechia; Germany; Hungary; New Zealand (ClinicalTrials.gov record NCT01028963, source copy `cardio:ctgov-nct01028963-2025-03-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01028963-2025-03-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Placebo
- Intervention (Drug): pioglitazone
- Intervention (Drug): CCX140-B
- Intervention (Drug): CCX140-B
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: a60a479cec42888808c386a7b44bf4c01e7cb67bc3e6e3d0522343b576a44a36
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
